Teva
says hoping to
launch EpiPen-like device by
2018 in U.S.
(Reuters) –
Teva Pharmaceutical Industries Ltd said Friday it hoped to win
U.S. approval by late 2017 or early
2018 for its version of Mylan NV’s EpiPen
device for treating severe allergic reactions, a move that would challenge the branded product’s overwhelming market dominance.
